Stay updated on Phase 2 Study of CPI-0610 Combo in Myelofibrosis Clinical Trial
Sign up to get notified when there's something new on the Phase 2 Study of CPI-0610 Combo in Myelofibrosis Clinical Trial page.

Latest updates to the Phase 2 Study of CPI-0610 Combo in Myelofibrosis Clinical Trial page
- Check3 days agoChange DetectedThe page has been updated to Revision: v3.0.2, replacing v3.0.1, indicating an update to the content. The Back to Top element was removed, a minor UI change.SummaryDifference0.4%
- Check10 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1.SummaryDifference0.4%
- Check17 days agoChange DetectedThe webpage has undergone significant updates, including the addition of new facility names and locations, as well as detailed drug information related to Ruxolitinib and various blood disorders. Several previous entries have been removed, particularly related to specific locations and diseases.SummaryDifference25%
- Check24 days agoChange DetectedThere are no significant changes to the web page content.SummaryDifference0.3%
- Check31 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.8%
- Check38 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.9%
Stay in the know with updates to Phase 2 Study of CPI-0610 Combo in Myelofibrosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase 2 Study of CPI-0610 Combo in Myelofibrosis Clinical Trial page.